Headquartered in 5220 Valiant Court, Gloucester Fiscal year ends December NASDAQ: LIVN livanova.com
LivaNova PLC is a global medical technology company with nearly five decades of experience, focused on neurological and cardiac conditions. The company operates through two business segments: Cardiopulmonary, which provides perfusion systems, oxygenators, and related consumables used in cardiac surgery; and Neuromodulation, which offers implantable neurostimulation devices primarily for the treatment of drug-resistant epilepsy and is exploring applications in obstructive sleep apnea through proximal hypoglossal nerve stimulation therapy. LivaNova has approximately 3,300 employees and a commercial presence in more than 100 countries. Key products include the Essenz Perfusion System and the PolySync programming algorithm for neuromodulation. The company is listed on Nasdaq under the ticker LIVN. Updated
Monday's top analyst upgrades and downgrades included Altria, Archer Daniels Midland, Baidu, Beyond Meat, Bunge, General Electric, Hecla Mining, Kraft Heinz, Lowe’s Companies, Mosaic, Philip Morris International, Rivian Automotive, SLM, Sunrun, Toast,…
Thursday's top analyst upgrades and downgrades included Carvana, FedEx, First Solar, Generac, Nike, PagSeguro Digital, Palantir Technologies, Redfin, Regions Financial, Starbucks, Target and Workday.
LivaNova PLC is a global medical technology company with nearly five decades of experience, focused on neurological and cardiac conditions.
The Wall Street consensus 12-month price target for LIVN is $90.55.
